Welcome to our dedicated page for Theravance Biopharma SEC filings (Ticker: TBPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Theravance Biopharma, Inc. filings document operating results, material events, governance matters, and portfolio disclosures for a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual financial updates, YUPELRI collaboration revenue, business updates, Regulation FD materials, and financial-condition disclosures tied to the company’s therapeutics business.
The filing record also covers product and intellectual-property matters, including a Hatch-Waxman settlement resolving ANDA patent litigation involving YUPELRI® (revefenacin) inhalation solution. Other disclosures address the ampreloxetine Phase 3 CYPRESS outcome, costs associated with organizational restructuring and program wind-down activities, annual general meeting voting matters, director elections, and proxy governance.
Theravance Biopharma director Dean J. Mitchell received equity compensation, gaining 6,009 ordinary shares and a grant of options for 13,398 ordinary shares. The options have an exercise price of $16.64 per share and vest monthly, with remaining unvested options vesting by the next annual shareholder meeting if service continues.
Theravance Biopharma director Donal O'Connor received new equity awards. On June 12, 2026, he was granted 6,009 Ordinary Shares at no cost, increasing his direct holdings to 80,213 Ordinary Shares.
He was also granted a share option for 13,398 Ordinary Shares at an exercise price of $16.64 per share, expiring on June 11, 2036. According to the vesting terms, 1/12 of the option shares vest after each continuous month of service following the grant date, with any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders, provided he remains in continuous service.
Theravance Biopharma director Deepika Pakianathan received new equity compensation awards. On June 12, 2026, she acquired 6,009 Ordinary Shares at a price of $0.00 per share, increasing her direct holdings to 64,074 Ordinary Shares.
On the same date, she was also granted a Share Option (Right to Buy) covering 13,398 Ordinary Shares with an exercise price of $16.64 per share, expiring on June 11, 2036. According to the vesting terms, 1/12 of the option vests after each month of continuous service following the grant, with remaining unvested shares vesting on the date of the next annual shareholders’ meeting if service continues.
TBPH files a Rule 144 notice registering 13,314 shares of restricted common stock for sale. The filing lists 13,314 shares under "Securities To Be Sold" and records a prior disposition of 31,067 shares by Rhonda Farnum on 03/16/2026 for $433,637.11.
The broker listed is Morgan Stanley Smith Barney LLC and the exchange is shown as NASDAQ with a date field of 06/15/2026. Timing, method, and recipient of proceeds for the registered shares are not detailed in the excerpt.
Theravance Biopharma, Inc. reported the results of its 2026 Annual General Meeting of Shareholders held on June 12, 2026. Shareholders holding 47,059,878 ordinary shares, or 91.4% of shares entitled to vote, were present, providing a quorum to conduct business.
All director nominees, including Laurie Smaldone Alsup, Susannah Gray, Dean J. Mitchell, Donal O’Connor, Deepika R. Pakianathan, and Rick E. Winningham, were elected to serve until the 2027 annual meeting. Shareholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
In addition, shareholders approved a non-binding advisory resolution on the compensation of the company’s named executive officers, indicating overall support for the current executive pay program.
Theravance Biopharma, Inc. chief executive officer Rick E. Winningham reported a routine tax-related share withholding. On May 20, 2026, 20,038 Ordinary Shares were withheld at $16.55 per share to satisfy tax obligations from vesting restricted stock units, in a transaction with the company rather than in the open market.
After this withholding, he directly held 1,631,056 Ordinary Shares. He also reported indirect holdings of 92,567 Ordinary Shares held by a trust and 23,400 Ordinary Shares held as custodian.
Theravance Biopharma, Inc. reported that SVP & Chief Financial Officer Aziz Sawaf had 8,670 Ordinary Shares withheld at a price of $16.55 per share to cover tax obligations from vesting restricted stock units. This was a share withholding with the company, not an open market trade. After this routine tax-withholding transaction, Sawaf directly holds 344,953 Ordinary Shares.
Theravance Biopharma SVP Aine Miller reported a routine tax-withholding transaction related to equity compensation. On the vesting of previously granted restricted stock units, 6,827 Ordinary Shares were withheld at $16.55 per share to satisfy tax obligations in a transaction with the issuer, not the open market. After this withholding, Miller directly holds 177,334 Ordinary Shares.
Theravance Biopharma SVP Brett A. Grimaud had 8,829 Ordinary Shares withheld at $16.55 per share to cover taxes on vested restricted stock units. The shares were withheld by the company, not sold in the open market. After this tax-withholding transaction, he directly holds 363,120 Ordinary Shares.
Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported a routine tax-withholding share disposition tied to equity compensation. On the vesting of previously granted restricted stock units, 5,678 Ordinary Shares were withheld at $16.55 per share to satisfy tax obligations. The shares were withheld by the company and did not involve any open-market transaction. After this non-market disposition, Farnum directly holds 245,771 Ordinary Shares, indicating she retains a substantial equity stake following the tax payment event.